Michelle Gayari

Michelle Gayari, Executive Vice President, Global Operational Excellence and Innovation and member of the Executive Team at MMS, leads the global technical, medical and scientific functions. She has more than 20 years of experience in clinical research, including career highlights at the Mayo Clinic and Pfizer, prior to joining MMS.

Michelle’s long tenure in the data service area and commitment to excellence, fosters a culture across our global offices that attracts the best talent. Her global operational teams are responsible for all elements of clinical trial data strategies and tech-enabled services, including specialized expertise in all data and summarization steps leading to successful NDA submissions globally. Michelle established a Center of Excellence within the global operational teams that bring value beyond the deliverable, emphasizing strong science and process. Metrics and a strong emphasis on service delivery methodology drive the organization. Her teams lend their expertise to client sponsors ensuring the highest level of customer satisfaction and return on their investment.

The growth that MMS has experienced since day one is truly due to the people in our offices across the world. We’ve been able to not only develop highly talented professionals but we play a critical role in the process of bringing life altering drugs to market. I like to say that “good work rises to the top,” and I am continually reminded of that every day.
Michelle Gayari
Executive Vice President, Global Operational Excellence and Innovation

She earned her BS in Statistics, Mathematics, and Psychology from Central Michigan University. Michelle’s commitment to mentoring and education extends to the community, including a board position on T.E.A.C.H. and continued expansion of MMS Academy curriculum.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization